Bispecific Antibody Market Outlook:
Bispecific Antibody Market size was over USD 15.27 billion in 2025 and is poised to exceed USD 426.17 billion by 2035, growing at over 39.5% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of bispecific antibody is estimated at USD 20.7 billion.
The bispecific antibody market is primarily driven by a rise in the occurrence of cancer afflictions, such as hematological and other hard-to-treat malignancies, around the globe. According to the American Cancer Society, the number of new and death cases of cancer in the world accounted for 20.0 million and 9.7 million in 2022, respectively. It also predicted the count habitats affected by this condition to surpass 35.0 million by 2050. On the other hand, the Journal of Global Health revealed that the incidence and deaths due to multiple myeloma is poised to reach 2,15,313.3 and 1,58,095.1 by 2030. This demography signifies the increasing worldwide need for highly effective and tailored therapeutics, where bispecific antibodies (BsAbs) has shown promising results in targeting and treating carcinoma cells.
The recent boom in the immunotherapy industry is evolving the approach toward cancer care by introducing comparatively affordable payers’ pricing and less harsh alternatives. Simultaneously, several clinical evidence are identifying BsAbs to be one of the most suitable options to serve the same purpose. On this note, in October 2024, a Leukemia Research paper was published by ScienceDirect, demonstrating 99.0% probability of blinatumomab being cost-effective in treating children with B‑precursor acute lymphoblastic leukemia in Mexico. This therapy helped residents with high-risk first-relapse achieve 5.1 years of lifetime at an incremental cost of USD 31691.5, in comparison to standard consolidation chemotherapy. Currently, more explorations in the market are being conducted to discover wider applications.
